Table 5.

Major adverse events within 3 months in the two groups

Clinical outcomes	Cys C criteria		P	sCr criteria		P
	CIN (N=52)	Non‐CIN (N=161)		CIN (N=17)	Non‐CIN (N=196)
Renal replacement therapy, n (%)	0	0		0	0
In‐hospital death, n (%)	0	0		0	0
3‐mo death, n (%)	4 (7.7)	4 (2.5)	.102	6 (35.3)	2 (1.0)	.000
Progressed to CKD/ESRD, n (%)	0	0		0	0

CKD, chronic kidney disease; ESRD, end‐stage renal disease.